|
|||||
|
|
Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial |
|
| Authors: | Paul F. Schellhammer Gerald Chodak James B. Whitmore Robert Sims Mark W. Frohlich Philip W. Kantoff |
| Affiliation: | 1. Department of Urology, Eastern Virginia Medical School of Virginia, Norfolk, VA;2. Midwest Prostate and Urology Health Center, Weiss Memorial Hospital, Chicago, IL;3. Dendreon Corporation, Seattle, WA;4. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA |
| Abstract: | |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |